245 related articles for article (PubMed ID: 25556458)
1. Risk of treatment related death and febrile neutropaenia with first line palliative chemotherapy for de novo metastatic breast cancer in clinical practice in a middle resource country.
Phua CE; Tang WH; Yusof MM; Saad M; Alip A; See MH; Taib NA
Asian Pac J Cancer Prev; 2014; 15(23):10263-6. PubMed ID: 25556458
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine pattern of usage, rate of febrile neutropaenia and treatment related death in asian cancer patients in clinical practice.
Phua VC; Wong WQ; Tan PL; Bustam AZ; Saad M; Alip A; Wan Ishak WZ
Asian Pac J Cancer Prev; 2015; 16(4):1449-53. PubMed ID: 25743814
[TBL] [Abstract][Full Text] [Related]
3. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Phua CE; Bustam AZ; Yusof MM; Saad M; Yip CH; Taib NA; Ng CH; Teh YC
Asian Pac J Cancer Prev; 2012; 13(9):4623-6. PubMed ID: 23167391
[TBL] [Abstract][Full Text] [Related]
4. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
Klar N; Rosenzweig M; Diergaarde B; Brufsky A
Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
[TBL] [Abstract][Full Text] [Related]
5. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Serpico D; Porcu L; Tessari A; Gevorgyan A; Bregni G; Galli G; de Braud F; Torri V; Di Cosimo S
Clin Transl Oncol; 2015 Jul; 17(7):530-8. PubMed ID: 25604128
[TBL] [Abstract][Full Text] [Related]
6. Primary and secondary distant metastatic breast cancer: two sides of the same coin.
Güth U; Magaton I; Huang DJ; Fisher R; Schötzau A; Vetter M
Breast; 2014 Feb; 23(1):26-32. PubMed ID: 24215983
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
8. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate.
Licchetta A; Correale P; Migali C; Remondo C; Francini E; Pascucci A; Magliocca A; Guarnieri A; Savelli V; Piccolomini A; Carli AF; Francini G
J Chemother; 2010 Jun; 22(3):201-4. PubMed ID: 20566427
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
10. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
Kozloff M; Chuang E; Starr A; Gowland PA; Cataruozolo PE; Collier M; Verkh L; Huang X; Kern KA; Miller K
Ann Oncol; 2010 Jul; 21(7):1436-1441. PubMed ID: 20032126
[TBL] [Abstract][Full Text] [Related]
11. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
13. Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.
Galli G; Tessari A; Porcu L; Bregni G; Paolini B; Carcangiu ML; Gennaro M; De Santis MC; Lozza L; de Braud F; Di Cosimo S
Breast Cancer; 2017 Jul; 24(4):635-641. PubMed ID: 28058615
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
Onyenadum A; Gogas H; Markopoulos C; Bafaloukos D; Aravantinos G; Mantzourani M; Koutras A; Tzorakoelefterakis E; Xiros N; Makatsoris T; Fountzilas G; Kalofonos HP
J Chemother; 2007 Oct; 19(5):582-9. PubMed ID: 18073159
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of oxaliplatin in patients with metastatic breast cancer.
Delpeuch A; Leveque D; Rob L; Bergerat JP
Anticancer Res; 2011 May; 31(5):1765-7. PubMed ID: 21617237
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy in patients with distant metastatic breast cancer.
Steinauer K; Gross MW; Huang DJ; Eppenberger-Castori S; Güth U
Radiat Oncol; 2014 May; 9():126. PubMed ID: 24885766
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
19. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
20. Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.
Adjogatse D; Thanopoulou E; Okines A; Thillai K; Tasker F; Johnston SR; Harper-Wynne C; Torrisi E; Ring A
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):692-6. PubMed ID: 24909701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]